This opportunity aims at establishing and advancing promising early career investigators from across Canada with a focused commitment to undertaking cancer research. Through the CCS Emerging Scholar Research Grants, early career investigators will develop their cancer research programs in Canada and pursue important scientific advances of the highest quality and potential for impact in the four pillars of health research (biomedical; clinical; health services; and social, cultural, environmental & population health).

The purpose of the PRAs is to identify and support emerging researchers with interest in furthering knowledge on social and emotional skills (SES) and the future of work.

For more information, please click here.

Each year, RSRPP funds researchers across Ontario to study key road safety challenges and develop novel and actionable ways to make Ontario's roads safer. RSRPP projects take on average between one to three years to complete and typically do not exceed $50,000 per year in program funding. Selected partners must conduct applied road safety research using methodologies that the Ministry of Transportation cannot perform internally. This includes research that leverages any form of specialized equipment or resources such as private data sources, survey studies, simulator testing, or clinical expertise, as examples. Only studies that cannot be performed by MTO personnel are eligible for program funding.

Guidelines

Application Form

Brain Canada and ALS Canada share a strong belief that it is crucial that promising young investigators are nurtured in the early stages of their careers so they can strive to promote discovery and advancement.

The intent for this award is to attract the brightest young minds to ALS research, which will contribute to a succession plan for the Canadian ALS research community. This program is designed to nurture and support innovative ideas and compelling breakthroughs across the spectrum of ALS research.

A $315,000 pool of funds will be available for this program. Each Doctoral Award would be funded at $25,000 per year for up to three years, and each Postdoctoral Fellowship would be funded at $55,000 per year for up to three years. The funds awarded through this fellowship will be utilized to support the stipend/salary of the awardee(s).

CQDM’s Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. Projects selected as part of the Quantum Leap program focus on developing cutting-edge technologies with the potential to significantly advance the R&D activities of CQDM’s pharmaceutical members. Quantum Leap projects are executed in close collaboration and with the expert support and funds of pharmaceutical members.

The enabling technologies, innovative platforms and/or innovative therapies derived from the Quantum Leap pharma-led funding program for drug discovery research are selected for their potential to significantly improve, facilitate and/or accelerate the drug discovery process and the development of safer and more effective drugs. The technologies of interest can be at any stage of the drug development process and involve a wide range of therapeutic indications.

Projects are associated with specific deliverables and must be ready for use by CQDM pharmaceutical members upon completion. For scientists, the funded research opens new collaboration opportunities with world-class stakeholders in the industry.

• Inclusive collaborator
• Barrier breaker
• Research leader 

• demonstrate commitment to building Canada’s future and alignment with Killam attributes
• are mid-career researchers who usually completed their PhD no more than 15 years prior, though special circumstances may result in applicants being more or less than 15 years post-PhD.
• are employed at a Canadian research institution.

• humanities
• social sciences
• natural sciences
• health sciences
• engineering

If you are interested in being nominated for this prize, please contact Dr. Batia Stolar, Associate Vice-President, Research and Graduate Studies, at  bstolar@lakeheadu.ca

The FY23 Defense Appropriations Act provides funding for the Ovarian Cancer Research Program (OCRP) to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service Members, Veterans, their family members, and all women impacted by this disease.  The managing agent for the funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The FY23 OCRP funding opportunity announcements for the following award mechanisms are posted on the Grants.gov website.  .

Applications submitted to the FY23 OCRP must address one or more of the following Areas of Emphasis:

• Understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics, proteogenomics and other critical events

• Develop novel therapeutic strategies for treatment and prevention
• Identify and develop new strategies for screening, early-stage detection, prevention, accurate diagnosis, and prognosis
• Identify and implement strategies to improve the survivorship and quality of life
• Address health disparities
• Improve precision medicine

Alternatively, with adequate justification, applications may identify and address another area of importance related to the ovarian cancer. Justification must be provided in the application.

https://cdmrp.health.mil/funding/ocrp

Investigator-Initiated Research Award – Preproposal due April 17, 2023

Investigators at or above the level of Assistant Professor (or equivalent).

Partnering PI Option:  Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award. 

Supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care.

•           Clinical trials are not allowed.

•           If cell lines or animals are used, justification for use is required.

•           Research aimed at extending the lives of advanced state and recurrent patients is encouraged.

•           Preliminary data are required.

•           Pre-application is required; application submission is by invitation only. 

• ·      The maximum allowable funding for the entire period of performance is:
• ·      $600,000 for direct costs for a single PI.
• ·      $800,000 for direct costs for Partnering PIs
• ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·      The maximum period of performance is 4 years.

Ovarian Cancer Academy Award- Early-Career Investigator – Preproposal due April 17, 2023

Investigators must be within 5 years of their last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent as of the full application submission deadline.  A letter attesting to eligibility is required.

Supports the addition of new Early-Career Investigators (ECIs) to the unique, interactive virtual academy that provides intensive mentoring, national networking, collaborations, and a peer group for junior faculty.

•           ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.

•           A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.

•           A Designated Mentor may only mentor one ECI.

•           The Designated Mentor is not required to be at the same institution as the ECI.

•           Preliminary data are required.

•           Clinical trials are allowed.

•           Pre-application is required; application submission is by invitation only.

•           The maximum allowable funding for the entire period of performance is $725,000 for direct costs.

•           Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•           The maximum period of performance is 4 years

Pilot Award – Preproposal due April 17, 2023

Investigators at the level of postdoctoral fellow or clinical fellow (or equivalent).

Supports innovative, high-risk/high-reward research in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.

•           Innovation is an important review criterion.

•           The goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.

•           Clinical trials are not allowed.

•           Research aimed at extending the lives of advanced-state and recurrent patients is encouraged.

•           Pre-application is required and blinded; application submission is by invitation only.

•           The maximum allowable funding for the entire period of performance is $300,000 for direct costs.

•           Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•           The maximum period of performance is 2 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final funding opportunity announcements available for downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBRAP.org

For more information, please contact Jill Sherman at intl.research@lakeheadu.ca .